Meril Life Sciences has shared one-year outcomes from the pivotal LANDMARK RCT at PCR London Valves 2025, confirming comparable efficacy and superior extended clinical outcomes for the Myval THV series alongside the lowest regurgitation rates among leading transcatheter valves.
